Electronic Supplementary Information

Biological activities tuning of antibacterial urotorpine *via* co-crystallization: Synthesis, biological activity evaluation and computational insight

Nida Tabassum¹, Panayiotis C. Varras², Fiza Arshad¹, Muhammad I. Choudhary^{1,3,4}, and Sammer Yousuf^{1*}

1- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan.

2- Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, GR-45110 Ioannina, Greece.

3- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan.

4- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah-21412, Saudi Arabia.



Fig. S1 (A) DSC Spectra of urotropine (1) (API), syringic acid (coformer) and urotropine: syringic acid (1:1) co-crystal 2. (B) TGA spectra of urotropine (1) (API), syringic acid (coformer), and urotropine: syringic acid (1:1) co-crystal 2.



Fig. S2 (A) DSC Spectra of urotropine (1) (API), 4-[4-(trifluoromethyl) phenoxy] phenol (coformer) and urotropine: 4-[4-(trifluoromethyl) phenoxy] phenol (1:1) co-crystal **3**. (**B**) TGA Spectra of urotropine (1) (API), 4-[4-(trifluoromethyl) phenoxy] phenol (coformer), and urotropine: 4-[4-(trifluoromethyl) phenoxy] phenol (1:1) co-crystal **3**.



Fig. S3 (A) DSC Spectra of urotropine (1) (API), *trans*-cinnamic acid (coformer) and urotropine: *trans*-cinnamic acid (1:1) co-crystal **4**. (**B**) TGA Spectra of urotropine (1) (API), *trans*-cinnamic acid (coformer), and urotropine: *trans*-cinnamic acid (1:1) co-crystal **4**.



Fig. S4 Molecular structures of synthesized co-crystals obtained at ω B97XD/6311++G(d,p) level of theory.



Fig. S5 The HOMO-LUMO energy gap of synthesized co-crystals, calculated at ω B97XD/6311++G(d,p) level of theory.



Fig. S6 Generated 2D Hirshfeld surface for urotropine: syringic acid 1:1 co-crystal **2** on de and di parameters.



Fig. S7 Shape-index and curvedness mapped over Hirshfeld surface for urotropine: syringic acid 1:1 co-crystal **2**.



Fig. S8 (A) Generated 2D Hirshfeld surface for urotropine: syringic acid 1:1 co-crystal **2** on dnorm parameters. (B) Urotropine: syringic acid 1:1 co-crystal interactions with generated Hirshfeld surface.



Fig. S9 2D Fingerprint plots representation of urotropine: syringic acid 1:1 co-crystal 2.



Fig. S10 Generated 2D Hirshfeld surface for urotropine: 4-[4-(trifluoromethyl)phenoxy] phenol 1:1 co-crystal **3** on de and di parameters.



Fig. S11 Shape-index and curvedness mapped over Hirshfeld surface for urotropine: 4-[4-(trifluoromethyl)phenoxy] phenol 1:1 co-crystal **3**.



Fig. S12 (A) Generated 2D Hirshfeld surface for urotropine: 4-[4-(trifluoromethyl)phenoxy] phenol 1:1 co-crystal **3** on dnorm parameters. (B) Urotropine: 4-[4-(trifluoromethyl)phenoxy] phenol 1:1 co-crystal **3** interactions with generated Hirshfeld surface.



Fig. S13 2D Fingerprint plots representation of urotropine: 4-[4-(trifluoromethyl)phenoxy] phenol 1:1 co-crystal **3**.



Fig. S14 Generated 2D Hirshfeld surface for urotropine: *trans*-cinnamic acid 1:1 co-crystal **4** on de and di parameters.



curvedness

Shape-index

Fig. S15 Shape-index and curvedness mapped over Hirshfeld surface for urotropine: *trans*-cinnamic acid 1:1 co-crystal **4**.



Fig. S16 (A) Generated 2D Hirshfeld surface for urotropine: *trans*-cinnamic acid 1:1 co-crystal **4** on dnorm parameters. (B) Urotropine: *trans*-cinnamic acid 1:1 co-crystal **4** interactions with generated Hirshfeld surface.



Fig. S17 2D Fingerprint plots representation of urotropine: trans-cinnamic acid 1:1 co-crystal 4.

D	Н	Α	D-H	HA	DA	D-HA
01	H1	N4 ^{#1}	0.84	1.83	2.638(1)	160
O4	H4	N2 ^{#2}	0.84	2.10	2.828(1)	144
C8	H8C	O1#3	0.98	2.50	3.421(1)	157
C14	H14B	O2 ^{#4}	0.99	2.38	3.334(1)	162

Table S1 The list of selected hydrogen bonds geometry (Å) in co-crystal 2.

Symmetric codes #1: -x+1,-y,-z+1 #2: x-1/2,-y+1/2,z+1/2 #3: x-1,y,z #4: -x,-y,-z+1

Table S2 The list of selected hydrogen bonds geometry (Å) in co-crystal 3.

D	Н	Α	D-H	НА	DA	D-HA
01	H1	N2#1	0.84	1.93	2.754	167
C6	H6	N3 ^{#2}	0.95	2.60	3.530	168
C14	H14A	N4 ^{#3}	0.99	2.50	3.465	163

Symmetric codes #1: x,-y-1/2,z+1/2 #2: -x,y-1/2,-z+3/2 #3: x,y-1,z

D	Н	Α	D-H	HA	DA	D-HA
02	H1'	N1 ^{#1}	1.02	1.64	2.646(1)	168
C10	H10A	N3 ^{#2}	0.99	2.54	3.514(1)	170

Table S3 The list of selected hydrogen bonds geometry (Å) in co-crystal 4.

Symmetric code#1: x,y,z-1 #2: -x+1,-y+2,z+1/2

Table S4 The comparison of FT-IR spectra stretching frequency values in cm⁻¹ for urotropine (1) (API), syringic acid (coformer of co-crystal 2), 4-[4-(trifluoromethyl) phenoxy] phenol (coformer of co-crystal 3), *trans*-cinnamic acid (conformer of co-crystal 4), and co-crystals 2, 3, and 4.

Functional Groups	C=O	C=C	C-0	C=C	O-H	О-Н	C-N
				(Aromatic)	(COOH)	(Phenol)	
Urotropine (1)	-	-	-	-	-	-	1237
(API)							
Syringic acid	1699	-	1246-1112	1461-1618	3247	3374	-
(coformer of co-crystal 2)							
4-[4-(trifluoromethyl)	-	-	1225	1446-1614	-	3294	-
phenoxy] phenol							
(coformer of co-crystal 3)							
Trans-cinnamic acid	1667	1626	1312	1419-1493	2522-2833	-	-
(coformer of co-crystal 4)							
Co-crystal 2	1572	-	1250-1120	1420-1518	3090-3895	3403	1286
Co-crystal 3	-	-	1194	1465-1613	-	3960	1238
Co-crystal 4	1689	1620	1374	1394-1493	3326-3587	-	1238